Related Experiment Video

Updated: Apr 8, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

2.2K

Correction to: GPX4 is a key ferroptosis regulator orchestrating T cells and CAR-T-cells sensitivity to ferroptosis

Marta Kłopotowska1, Iwona Baranowska1, Szymon Hajduk1,2

  • 1Department of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences, 5 Adolfa Pawinskiego St., 02-106, Warsaw, Poland.

Cancer Immunology, Immunotherapy : CII
|April 7, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.7K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.5K

Related Experiment Videos

Last Updated: Apr 8, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

2.2K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.7K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.5K

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

8.0K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
8.0K

Articles linked to this work by shared authors, journal, and citation graph.

dcHiChIP: a comprehensive Nextflow-based pipeline for multiscale analysis of chromatin architecture from HiChIP data.

Bioinformatics (Oxford, England)·2026

Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.

Leukemia·2026

The transcription factor BACH1 couples chromatin priming and repression to enable macrophage plasticity and adaptation.

Immunity·2026

The dual role of lectins in cancer-immunotherapy tools and therapeutic targets.

FEBS letters·2026

RepliSage: a stochastic graph-based framework for 3D chromatin modeling across the cell cycle.

Nucleic acids research·2026

De novo design of anticancer 4-thiazolidinone derivatives: a generative framework shaped by activity cliffs.

Journal of cheminformatics·2026

Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer-a monocentric experience.

Cancer immunology, immunotherapy : CII·2026

The CREM-IL-15 axis: decoding the persistence-exhaustion paradox in NK cell immunotherapy.

Cancer immunology, immunotherapy : CII·2026

Dual inhibition of tumor cells and tumor-associated neutrophils by anti-CXCR2 antibodies suppresses tumor growth and augments immunotherapy efficacy in ARID1A-deficient pancreatic cancer.

Cancer immunology, immunotherapy : CII·2026

Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma.

Cancer immunology, immunotherapy : CII·2026

Mast cells in tumors: dual roles and therapeutic potential.

Cancer immunology, immunotherapy : CII·2026

Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma.

Cancer immunology, immunotherapy : CII·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us